The authors noted that the contribution of difficult-to-detect variant types, paired with the fact that tumor sequencing studies often do not systematically assess germline alleles, might underlie the low reported frequency of BRCA2 mutations in earlier prostate cancer sequencing studies. The gene discussed is BRCA2; the disease is prostate cancer.